N-tert-butyl 2-hydroxy-2-(pyridin-4-yl)ethanesulfonamide | 275384-06-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-tert-butyl 2-hydroxy-2-(pyridin-4-yl)ethanesulfonamide
• 英文别名: N-tert-butyl-2-hydroxy-2-(pyridin-4-yl)ethanesulfonamide；N-tert-butyl-2-hydroxy-2-(4-pyridyl)ethanesulfonamide；N-tert-butyl-2-hydroxy-2-pyridin-4-ylethanesulfonamide
• CAS: 275384-06-0
• 化学式: C₁₁H₁₈N₂O₃S
• 分子量: 258.342
• InChiKey: FVDCTSPDMRNPGK-UHFFFAOYSA-N

物化性质

• 沸点：
  436.7±55.0 °C(Predicted)
• 密度：
  1.232±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  87.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-tert-butyl 2-hydroxy-2-(pyridin-4-yl)ethanesulfonamide 在 吡啶 、 盐酸 、 碳酸氢钠 、 sodium chloride 、 乙酸酐 、 N,N'-羰基二咪唑 作用下， 以 乙醚 、 乙醇 、 水 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 三氟乙酸 为溶剂， 生成 3-(2-chloro-4-phenylbenzyl)-2-methyl-5-[(E)-[2-(4-pyridyl)ethene]sulfonylcarbamoyl]-3H-imidazo[4,5-b]pyridine
  参考文献：
  名称：

  Sulfonamide compounds and uses thereof as medicines

  摘要：

  本发明涉及一种具有以下结构式(I)的磺胺类化合物：其中每个符号如规范中定义，其盐以及含有该化合物的药物组合物。该化合物可以作为一种有效的药剂，用于预防和治疗基于降糖作用可治愈的疾病，以及基于cGMP-PDE抑制作用、平滑肌松弛作用、支气管扩张作用、血管扩张作用、平滑肌细胞抑制作用和抗过敏作用可治愈的疾病。

  公开号：

  US06573274B1
• 作为产物：
  描述：

  4-吡啶甲醛 、 N-(叔丁基)-甲磺酰胺 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 以65%的产率得到N-tert-butyl 2-hydroxy-2-(pyridin-4-yl)ethanesulfonamide
  参考文献：
  名称：

  Ethenesulfonamide and ethanesulfonamide derivatives, a novel class of orally active endothelin-A receptor antagonists

  摘要：

  In the previous paper, we described a series of 2-phenylethenesulfonamide derivatives, a novel class of ET(A)-selective endothelin (ET) receptor antagonists, including the 2-methoxyethoxy derivative 2a and the 2-fluoroethoxy derivative (2b). In this paper, we wish to report further details of structure-activity relationships (SARs) of the two regions of the molecule in compound 2b, which were the alkoxy region at the 6-position of the core pyrimidine ring and the 2-phenylethenesulfonamide region. In these modifications, replacement of the 2-fluoroethoxy group with a methoxy group (6e) and replacement of the 2-phenylethenesulfonamide group with a 2-(pyridin-3-yl)ethenesulfonamide group (61) or 2-phenylethanesulfonamide group (6q) were well tolerated both in the ET(A) binding affinity and ET(A) selectivity. Among them, compound 6e showed further improvement in oral activity compared to 2b. After oral administration, compound 6e inhibited the big ET-1 induced pressor response in conscious rats at 0.3 mg/kg with a duration of >6.5 h. Compound 6e also exhibited a potent antagonistic activity in the pithed rats. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00187-0

文献信息

• SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1136492A1

  公开（公告）日：2001-09-26

  The present invention relates to a sulfonamide compound of the formula (I): wherein each symbol is as defined in the specification, a salt thereof, and a pharmaceutical composition containing same. This compound can be an effective agent for the prophylaxis and treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle cell inhibitory action and an allergy suppressing action.

  本发明涉及一种式 (I) 的磺酰胺化合物： 其中各符号如说明书中所定义的磺酰胺化合物、其盐和含有该化合物的药物组合物。该化合物可作为预防和治疗基于降血糖作用的疾病和基于 cGMP-PDE 抑制作用、平滑肌松弛作用、支气管扩张作用、血管扩张作用、平滑肌细胞抑制作用和过敏抑制作用的疾病的有效药物。
• US6573274B1
  申请人：——

  公开号：US6573274B1

  公开（公告）日：2003-06-03
• US6890934B2
  申请人：——

  公开号：US6890934B2

  公开（公告）日：2005-05-10
• Sulfonamide compounds and uses thereof as medicines
  申请人：Fujisawa Pharmaceutical Co. Ltd.

  公开号：US06573274B1

  公开（公告）日：2003-06-03

  The present invention relates to a sulfonamide compound of the formula (I): wherein each symbol is as defined in the specification, a salt thereof, and a pharmaceutical composition containing same. This compound can be an effective agent for the prophylaxis and treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle cell inhibitory action and an allergy suppressing action.

  本发明涉及一种具有以下结构式(I)的磺胺类化合物：其中每个符号如规范中定义，其盐以及含有该化合物的药物组合物。该化合物可以作为一种有效的药剂，用于预防和治疗基于降糖作用可治愈的疾病，以及基于cGMP-PDE抑制作用、平滑肌松弛作用、支气管扩张作用、血管扩张作用、平滑肌细胞抑制作用和抗过敏作用可治愈的疾病。
• Ethenesulfonamide and ethanesulfonamide derivatives, a novel class of orally active endothelin-A receptor antagonists
  作者：Hironori Harada、Jun-ichi Kazami、Susumu Watanuki、Ryuji Tsuzuki、Katsumi Sudoh、Akira Fujimori、Masanao Sanagi、Masaya Orita、Hideaki Nakahara、Jun Shimaya、Shin-ichi Tsukamoto、Akihiro Tanaka、Isao Yanagisawa

  DOI：10.1016/s0968-0896(01)00187-0

  日期：2001.11

  In the previous paper, we described a series of 2-phenylethenesulfonamide derivatives, a novel class of ET(A)-selective endothelin (ET) receptor antagonists, including the 2-methoxyethoxy derivative 2a and the 2-fluoroethoxy derivative (2b). In this paper, we wish to report further details of structure-activity relationships (SARs) of the two regions of the molecule in compound 2b, which were the alkoxy region at the 6-position of the core pyrimidine ring and the 2-phenylethenesulfonamide region. In these modifications, replacement of the 2-fluoroethoxy group with a methoxy group (6e) and replacement of the 2-phenylethenesulfonamide group with a 2-(pyridin-3-yl)ethenesulfonamide group (61) or 2-phenylethanesulfonamide group (6q) were well tolerated both in the ET(A) binding affinity and ET(A) selectivity. Among them, compound 6e showed further improvement in oral activity compared to 2b. After oral administration, compound 6e inhibited the big ET-1 induced pressor response in conscious rats at 0.3 mg/kg with a duration of >6.5 h. Compound 6e also exhibited a potent antagonistic activity in the pithed rats. (C) 2001 Elsevier Science Ltd. All rights reserved.